the productive form in which viral replication is independent o f the host chromosomal D N A synthesis, resulting in a large num ber o f virions. T he presence o f large numbers o f virions w ithin the cell results in a cytopathic effect, which is recognizable cytologically and histologically as acanthosis, cytoplasmic vacuolation, koilcytosis, multinucleation and nuclear atypia.
H um an papilloma virus seems to evade successfully the im m une system o f the body.10,11 A significant antibody response to infection is only seen in approximately 50% o f infected individuals. These antibodies are directed against the capsid proteins o f the virus. T he response however takes several m onths to develop. An existing high titer o f neutralizing antibody may successfully prevent infection by HPV. Delayed-type hypercellularity may also develop and may lead to regression o f lesions. This involves a cytotoxic T-cell response encompassing natural killer cells and antigenspecific cytotoxic T cells. T hat the role o f cell-mediated im m unity is im portant in control o f established infections is consistent with an increased prevalence o f H PV infection and cervical intraepithelial lesions in imm unocompromised patients.
T he natural history o f H PV infection is that most sexually active women are exposed to the virus after initiating sexual activity. T he risk o f infection is m uch greater in women who have multiple sex partners.1,5 M ost o f the women develop transient H P V infections, which last for several m onths but are eventually eliminated so that most o f these HPV-infected women become H PV negative. Acquisition o f H PV infection and its eventual clearance is a dynamic process in which several additional factors come into play and determine the final outcome. T hus women who have multiple partners may become infected repeatedly. Im m unity may also play an im portant role in elimination o f the virus. Furthermore, the viral elimination is m uch more rapid in infections by low-grade types such as 6 and 11. O nly a small proportion of women become persistently infected and continue to have detectable H PV D N A in genital epithelium one year after infection ( Figure 2 ). It is these persistently infected women who are at risk of developing intraepithelial neoplastic lesions and subsequently developing carcinoma.12 High-grade intraepithelial lesions and cervical cancer almost exclusively develop in women carrying infection by high-risk H PV types, especially type 16. T he transformation from high-grade intraepithelial lesion to invasive carcinoma takes approximately ten years. T he lesions caused by persistent infection by low-risk H PV are self-limiting and ultimately undergo regression.
Development o f cervical carcinoma and precancerous intraepithelial lesions is a complex multifactorial process in which infection by high-risk H PV plays a pivotal role. In addition several co-factors are also thought to contribute significantly towards development o f malignancy. These are E l, E2, E4, E5, E6, and E7. T he late region o f H P V is downstream o f the early region and contains two ORFs, term ed LI and L2, which encode viral capsid proteins (Figure 3 ). These may also give rise to virus-like particles (VLPs), which are composed o f capsid proteins w ithout the viral DNA.
Expression o f E6 and E7 proteins encoded by high-risk H P V such as 16 and 18 in established tissue culture cell lines causes the cells to become completely transformed. Such an effect is not evident w ith low-risk HPV. In addition to having in vitro transform ing activity, both E6 and E7 are always actively transcribed in cervical cancer, suggesting that unregulated expression o f these genes plays a significant role in carcinogenesis and m aintenance o f the m alignant phenotype. These proteins interact w ith cellular proteins such as p53 and the product o f retinoblatom a gene (pRb), which is normally responsible for controlling key steps in the cell cycle. P53 is a key cellular regulatory gene that acts as a transcriptional activator and has characteristics of a tumor suppressor gene. In non-infected cells, p53 levels increase in response to cellular or D N A damage or aberrant cellular proliferation signals. High levels of p53, by interacting with W A Fl/cipl and cdk-cyclin, induce the cell to undergo growth arrest in the G1 phase of the cell cycle, which provides an opportunity for the cell to either repair D N A damage or be eliminated through programmed cell death (apoptosis). In HPV-infected cells E6 protein from high-risk HPVs binds to p53 thus causing loss of its crucial role in controlling the cell cycle.15 pRb also plays a crucial role in controlling the transition from G1 to the S phase of the cell cycle by interacting with other cell cycle proteins including E2F, c-myc and n-myc. E7 encoded by high-risk HPVs binds with pRb, blocking its ability to interact with E2F and unregulated proliferation occurs.16 O n the other hand, E6 and E7 from low-risk HPVs have a lower affinity for p53 and pRB and therefore are not oncogenic (Figure 4 ).
Prevention Strategies
Cervical cytology screening has been significandy responsible for a declining incidence of cervical cancer in large parts of the world.17 Mass screening plays a preventive role by identifying precursor lesions, which can be treated effectively, thus reducing the prevalence of invasive cervical carcinoma. Since H PV infection is sexually transmitted, a change in sexual habits and behavior may also have a protective influence by preventing infection not only of H PV but also by other infectious agents such as HIV, HSV2 and Chlamydia trachomatis, which may act as co-factors for development of cervical cancer. Modulation of other co-factors such as smoking and long-term use of contraceptive hormones may also contribute toward prevention of malignant transformation. It is also important to provide public education to both men and women regarding the H PV infection and the steps that may be taken to prevent serious complications.
The most promising and exciting method for prophylaxis o f H PV infection and its complications is vaccination.6,18 In recent years significant strides have been made toward making vaccination for H PV a reality in the not too distant future.19,20 If successful, vaccination for H PV will have a dramatic impact on the control o f cervical cancer, the magnitude of which may far exceed that seen as a result o f cervical screening.
There are still many technical and practical problems and issues that need to be resolved before safe, effective and cost-effective vaccines become available for use in the general population.6 An important issue, which is still being discussed, is which o f the 30 or more oncogenic types o f H PV should be included in these vaccines. At present almost 80% of the cervical cancers are caused by H PV 16,18, 31 and 43. There is a concern that when vaccines against the common H PV types are used extensively the uncommon types may become more prevalent. There is still no consensus on the most suitable route o f administration of vaccines although nasal and oral routes may be preferable. The target population should o f course be girls but a case can be made for vaccination o f boys since male partners are the usual source o f infection. The vaccination may be administered during infancy or before the start o f sexual activity. The cost o f production and administration o f vaccines to the general public may also determine ultimate success or failure o f the project. The problem seems to be greater for the therapeutic vaccines although their production has moved into an industrial phase.
The projects and plans for the testing and production of H PV vaccines are exciting and there is great optimism that it will be ultimately successful, but it may be 10 to 15 years before these vaccines are available for use on the general public. In the meantime it is important that current methods o f surveillance and screening for cervical cancer and its precursor lesion be continued.
